Keryx Biopharma's perifosine gets fast track designation from US FDA to treat advanced colorectal cancer
Thursday, April 08, 2010 15:00 IST Quebec City, Canada
Æterna Zentaris Inc, a late-stage drug development company specialized in oncology and endocrine therapy, announced that its partner, Keryx Biopharmaceuticals, was granted